Thermo Fisher Scientific (NYSE:TMO) PT Raised to $632.00

Thermo Fisher Scientific (NYSE:TMO) had its price target lifted by Robert W. Baird from $620.00 to $632.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an outperform rating on the medical research company’s stock.

Several other brokerages have also weighed in on TMO. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an equal weight rating for the company in a report on Friday, June 28th. Jefferies Financial Group reaffirmed a buy rating and issued a $650.00 price objective (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a buy rating in a report on Thursday, April 25th. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an outperform rating on the stock in a research note on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an overweight rating in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of Moderate Buy and a consensus price target of $618.94.

Thermo Fisher Scientific Stock Up 2.1 %

TMO stock opened at $607.14 on Thursday. The company’s 50 day simple moving average is $563.01 and its 200-day simple moving average is $565.97. The firm has a market capitalization of $231.76 billion, a PE ratio of 38.94, a P/E/G ratio of 2.83 and a beta of 0.77. Thermo Fisher Scientific has a 12 month low of $415.60 and a 12 month high of $614.65. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.33.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.15 earnings per share. Equities analysts expect that Thermo Fisher Scientific will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Signature Resources Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. LifeSteps Financial Inc. acquired a new position in Thermo Fisher Scientific in the first quarter valued at about $31,000. New Millennium Group LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth about $29,000. Northwest Financial Advisors acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Finally, True Wealth Design LLC increased its stake in shares of Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after buying an additional 51 shares during the period. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.